Influencia de la puntuación MELD basal en la eficacia del tratamiento de la hepatitis C con sofosbuvir y simeprevir

2015, Recommendations on treatment of hepatitis C 2015, J Hepatol, 63, 199, 10.1016/j.jhep.2015.03.025 Gower, 2014, Global epidemiology and genotype distribution of the hepatitis C virus infection, Journal of Hepatology, 61, S45, 10.1016/j.jhep.2014.07.027 Calleja Panero, 2013, Prevalencia de marcadores serológicos de virus hepatotropos (B y C) en población trabajadora sana, Rev Esp Enferm Dig, 105, 249 Westbrook, 2014, Natural history of hepatitis C, J Hepatol., 61, 58, 10.1016/j.jhep.2014.07.012 Petta, 2016, Hepatitis C Virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies, Gastroenterology., 150, 145, 10.1053/j.gastro.2015.09.007 Liang, 2013, Current and future therapies for hepatitis C virus infection, N Engl J Med., 368, 1907, 10.1056/NEJMra1213651 Liang, 2014, Therapy of Hepatitis C — Back to the Future, N Engl J Med., 370, 2043, 10.1056/NEJMe1403619 Aqel, 2015, Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis, Hepatology., 62, 1004, 10.1002/hep.27937 Banerjee, 2016, Review arfticle: safety and tolerability of direct-acting antiviral agents in the era of hepatitis C therapy, Aliment Pharmacol Ther, 43, 674, 10.1111/apt.13514 Righi, 2015, Impact of new treatment options for hepatitis C virus infection in liver transplantation, World J Gastroenterol, 14, 10760, 10.3748/wjg.v21.i38.10760 Guías AEEH/SEIMC de manejo de la hepatitis C [consultado 29 May 2017]. Disponible en: https://www.seimc.org/contenidos/documentoscientificos/guiasclinicas/seimc-clinicasclinicas-2016-Manejo_HepatitisC.pdf. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-54. Sanford, 2015, Simeprevir: a review of its use in patients with chronic hepatitis C virus infection, Drugs., 75, 183, 10.1007/s40265-014-0341-2 Stedman, 2014, Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential, Therap Adv Gastroenterol., 7, 131, 10.1177/1756283X13515825 Lawitz, 2014, Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study, Lancet., 384, 1756, 10.1016/S0140-6736(14)61036-9 Kwo, 2016, Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study, Hepatology, 64, 370, 10.1002/hep.28467 Lawitz, 2016, Simeprevir plus sofosbuvir in chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2), Hepatology, 64, 360, 10.1002/hep.28422 Sulkowski, 2016, Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection, Gastroenterology, 150, 419, 10.1053/j.gastro.2015.10.013 García Comas, 2015, Prevalence of hepatitis C antibodies in the population aged 16-80 years in the Community of Madrid 2008-2009, J Med Virol., 87, 1697, 10.1002/jmv.24219 Pearlman, 2015, The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis, Gastroenterology., 148, 762, 10.1053/j.gastro.2014.12.027 Aqel, 2015, Sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis, Hepatology, 62, 1004, 10.1002/hep.27937